Palladium- and copper-mediated N-aryl bond formation reactions for the synthesis of biological active compounds

  1. Carolin Fischer and
  2. Burkhard Koenig

Institute of Organic Chemistry, University of Regensburg, Universitätsstr. 31, D-93053 Regensburg, Germany

  1. Corresponding author email

Dedicated to Prof. Henning Hopf on the occasion of his 70th birthday.

Associate Editor: I. Marek
Beilstein J. Org. Chem. 2011, 7, 59–74. doi:10.3762/bjoc.7.10
Received 14 Oct 2010, Accepted 14 Dec 2010, Published 14 Jan 2011


N-Arylated aliphatic and aromatic amines are important substituents in many biologically active compounds. In the last few years, transition-metal-mediated N-aryl bond formation has become a standard procedure for the introduction of amines into aromatic systems. While N-arylation of simple aromatic halides by simple amines works with many of the described methods in high yield, the reactions may require detailed optimization if applied to the synthesis of complex molecules with additional functional groups, such as natural products or drugs. We discuss and compare in this review the three main N-arylation methods in their application to the synthesis of biologically active compounds: Palladium-catalysed Buchwald–Hartwig-type reactions, copper-mediated Ullmann-type and Chan–Lam-type N-arylation reactions. The discussed examples show that palladium-catalysed reactions are favoured for large-scale applications and tolerate sterically demanding substituents on the coupling partners better than Chan–Lam reactions. Chan–Lam N-arylations are particularly mild and do not require additional ligands, which facilitates the work-up. However, reaction times can be very long. Ullmann- and Buchwald–Hartwig-type methods have been used in intramolecular reactions, giving access to complex ring structures. All three N-arylation methods have specific advantages and disadvantages that should be considered when selecting the reaction conditions for a desired C–N bond formation in the course of a total synthesis or drug synthesis.

Keywords: biologically active compounds; boronic acid; copper; N-arylation; palladium


Palladium- and copper-mediated N-arylations are important tools in organic synthesis. Due to the widespread importance of aryl-N bond formation, many synthetic methods have emerged over the years. Besides the traditional Ullmann [1,2] and Goldberg [3-5] procedures, the palladium-catalysed reaction discovered by Buchwald [6,7] and Hartwig [8,9] has been a major breakthrough in this field. More recently, Chan [10] and Lam [11,12] introduced the copper-mediated arylation of N-nucleophiles using stoichiometric copper(II) acetate and boronic acids. Collman improved the procedure using catalytic amounts of [Cu(OH)TMEDA]2Cl2, omitting the base and working at room temperature [13,14]. Besides palladium and copper, nickel catalysis also allows the arylation of primary and secondary amines [15,16]. However, the three methods (Ullmann–Goldberg, Buchwald–Hartwig and Chan–Lam) have become standard procedures for N-aryl bond formation, and many examples illustrate their wide application in organic synthesis.

The chelating phosphines BINAP, DPPF [17] and DtBPF [18], commonly used for the Buchwald–Hartwig amination, were recently displaced by the biaryl-(dialkyl)phosphine or arylphosphinepyrrole ligands [18-20]. Industrial scale-up of these methods has already been applied on the 100 kg scale for arylpiperazines and different diarylamines [21]. In addition, Nolan et al. and Organ et al. have reported Pd-N-heterocyclic carbene (NHC)-catalysed Buchwald–Hartwig amination protocols that provide access to a range of hindered and functionalized aryl amines [22-24]. Aryl bromides are most frequently applied as substrates for the coupling of primary and cyclic secondary amines [17]. In the presence of a weak base such as caesium carbonate, many functional groups are tolerated, while NaOt-Bu has limitations when base-labile functional groups are present. Electron-neutral and electron-poor aryl bromides are suitable substrates [17], and ortho-substituents on the aryl halide are tolerated. In contrast, electron-rich aryl bromides give only poor results. Recently, the modular synthesis of indoles by a palladium-catalysed cascade process provided an efficient entry to substituted indoles [25].

Although copper is less toxic and less expensive than palladium, the required harsh conditions, the limited range of suitable substrates and moderate yields prevented the use of Ullmann-type reaction from reaching its full potential for a long time. Aryl halides activated by electron-withdrawing groups can only be converted at high temperatures (210 °C) using stoichiometric amounts of copper. The discovery of efficient copper/ligand systems enabled the use of catalytic amounts of metal under milder conditions (90–100 °C) and resulted in good yields [4,26]. Copper-diamine-catalysed N-arylation facilitated the arylation of pyrroles, pyrazoles, indazoles, imidazoles, triazoles, benzimidazoles and indoles [27-29]. Besides aryl halides as the aryl donor, arylsiloxanes [30], arylstannanes [31], iodonium salts [32], aryl lead(IV) triacetates [33] and pentavalent organobismuth reagents [34] have also been used as aryl donors for copper-mediated C–N couplings.

Further improvement of N-arylation conditions was achieved by the use of arylboronic acids. The reagents are not sensitive to air; the reaction proceeds at room temperature [35,36] and in aqueous solution [37]. However, the reactions are very slow and require several hours or even days for completion [38].

In general, there are a wide variety of protocols describing the metal-mediated arylation of amines [17,37,39], amides [38], imides [38], imidazoles [14,37,40], benzimidazoles [40,41], sulfonamides [38], pyrroles [42] and lactams [43]. The three typical methods for N-arylation have been extensively reviewed concerning scope and limitation of these reactions [4,44-48].

However, the application of palladium- and copper-mediated N-arylation reactions in the synthesis of complex molecules such as natural products or drugs is, in comparison to standard small-molecule N-arylation, not always straightforward and requires specially optimized conditions. Since amine- and amide-substituted aromatics and heteroaromatics are typical structures in medicinal chemistry and natural product synthesis, a broad application of catalytic C–N-arylation is highly desirable.

Evano et al. recently reviewed copper-mediated C–N-arylation reactions in natural product syntheses and discussed different examples from total synthesis using the arylation of alkylamines, amides, carbamates, N-heterocycles, enamines and intramolecular N-arylation reactions [45].

We compare here the success of the different C–N-arylation reactions as applied to the synthesis of more complex structures and discuss selected examples of palladium- and copper-mediated reactions for the synthesis of bioactive compounds in terms of scope and limitation. If available, we directly compare the different methods and advantages of specific reaction conditions. The review should help synthetic chemists to select the most suitable catalytic C–N-arylation method for their target molecule.


Pd-catalysed synthesis of biological active molecules

A typical example for the application of palladium-catalysed N-aryl bond formation is the synthesis of highly selective D3 receptor ligands 4. Piperazine (1) and a substituted aryl bromide 2 (Scheme 1) are coupled in the initial step of the synthesis.


Scheme 1: Synthesis of selective D3 receptor ligands.

The electron-withdrawing substituents (nitrile and chloro) on the aryl bromide assisted the reaction, and reported yields of 3 are in the range of 65–90%. This method represents conditions from early catalyst generations and allowed the synthesis of a library of 18 compounds, which were investigated to identify a possible structure–activity relationship [49].

Federsel et al. used a piperazine derivative 6 and an aryl halide 5 for the preparation of a CNS-active substituted chiral aminotetralin 7 (Scheme 2) [50]. The 5-HT1B receptor antagonist 8 was developed for the treatment of certain neuronal disorders. Different syntheses have been developed in which Pd(OAc)2 proved to be the best catalyst in comparison to the dba complex, and BINAP the best ligand. There was no difference if the racemic or the enantiomeric pure ligand was used. The use of Pd(OAc)2 is advantageous on a larger scale due to low cost and easy handling. The choice of base was crucial. NaOMe and NaOEt gave only low conversions in comparison to NaOt-Bu. The reaction tolerated up to 0.06% water. Thus, the conditions could be optimized for the final use in a pilot plant in which batches of 125 kg were synthesized in a robust and reproducible manner [51].


Scheme 2: Synthesis of a novel 5-HT1B receptor antagonist.

Compound A-366833 (12) was found to be a broad-spectrum analgesic having an improved safety profile relative to other pyridine-containing analgesics. The efficient synthesis of this compound used a palladium-catalysed coupling for the final step connecting 3-bromo-5-cyanopyridine (9) with the protected (1R,5S)-3,6-diazabicyclo[3.2.0]heptane 10. The use of Cs2CO3 instead of the conventional base t-BuONa increased the yield of 11 from 47% to 73% (Scheme 3) [52]. The enantioselective synthesis of A-366833 allowed large-scale preparation required for preclinical investigations.


Scheme 3: Synthesis of A-366833, a selective α4β2 neural nicotinic receptor agonist.

Oxcarbazepine (13, Trileptal) is one of the most prescribed drugs for the treatment of epilepsy due to improved tolerability profile compared to carbamazepine. Additionally, its analgesic properties and successful treatment of mood disorders and mania make it an important therapeutic agent. In 2005, a new method that involved a cyclization step by intramolecular N-arylation of 14 was developed that led to improved access to compound 15 due to better availability of the starting material and a simple palladium source. Under optimized conditions, palladium catalysis yielded the tricyclic skeleton 15 in 91% and reduced the amount of dehalogenated by-product to 4% (Scheme 4). The beneficial effect of added water may be due to better dissolution of K3PO4. Scale-up to gram amounts was possible without any significant decrease in yield. The reaction failed with both copper-mediated Ullmann-type reactions and heterogeneous palladium catalysis [53].


Scheme 4: A new route to oxcarbazepine.

Intramolecular palladium-catalysed N-arylations have been applied to substituted arenes and thiophenes with good to excellent yields. Electron-rich bromides gave the best results, while pyridine derivatives were unreactive [54].

Another intramolecular approach enabled the stereoselective synthesis of an atropisomeric N-(2-tert-butylphenyl)lactam as an intermediate for norepinephrine transporter (NET) inhibitor 16. NET inhibitors were developed to treat a variety of mental disorders such as depression and attention deficit hyperactivity disorder (ADHD).

Screening different ligands, SERGPHOS appeared to give the highest stereoselectivity of 18 for the N-arylation of 17 (Scheme 5) [55]. Other conditions were not investigated in this case.


Scheme 5: Synthesis of key intermediates for norepinephrine transporter (NET) inhibitors.

Another example for BINAP not being the favoured ligand is the synthesis of the fungal natural product demethylasterriquinone A1 (19). Asterriquinones show different biological functions including anti-tumour activity and are used as insulin mimetics. The palladium-catalysed coupling of styrene 20 with sterically demanding N-nucleophiles 21 gave the indole building blocks 22 for the natural product synthesis (Scheme 6). In this case, P(t-Bu)3 was the appropriate ligand. As starting materials cyclic and aromatic amino compounds as well as substituted styrenes were tolerated (yields 61–85%). Only nitro-substituted styrene resulted in poor conversion (34%) [56].


Scheme 6: N-Annulation yielding substituted indole for the synthesis of demethylasterriquinone A1.

The synthesis of the natural product murrazoline is a further example of connecting a sterically demanding N-nucleophile at two positions. Murrazoline (23), a carbazole alkaloid isolated from the shrub Murraya, is used in folk medicine for the treatment of eczema, rheumatism and dropsy, as an analgesic, and in anaesthesia. It is known to be a potent platelet aggregation inhibitor. The double N-arylation of 25 was carried out under standard conditions using 24, and the best yield of 26 was achieved with the dicyclohexyl(2',4',6'-triisopropylbiphenyl-2-yl)phosphine ligand 27 (59%, Scheme 7) compared to the ligands, 28 and 29 [57].


Scheme 7: Palladium-catalysed double N-arylation contributing to the synthesis of murrazoline.

The synthesis of vitamin E amines 35, possessing anti-proliferative activity, could be realized by the easy and efficient procedure of coupling 30 to 31 or 33 according to Scheme 8. Enantiopure tocopheramines 32 and tocotrienamines 34 were synthesized using N-aryl amination as key the step. Here, the leaving group was triflate instead of the more commonly used halides and yields ranged from 10% to 80% [58].


Scheme 8: Synthesis of vitamin E amines.

An example illustrating both methods, i.e., the palladium- and the copper-catalysed N-arylation, is the synthesis of the natural product martinellic acid (36) and one of its derivatives (Scheme 9). The two alkaloids, martinellic acid (36) and martinelline (37), possess antagonist activity towards bradykinin B1 and B2 receptors. The key step of the synthetic sequence is the connection of an amino acid derivative to the aromatic core.


Scheme 9: Improved synthesis of martinellic acid.

Miyata et al. reported a nearly quantitative yield of 40 (99%) for the palladium strategy in the reaction between (S)-ethyl 5-oxopyrrolidine-2-carboxylate (39) and 2-bromobenzaldehyde O-benzyl oxime (38), and only a moderate yield (53%) using CuI [59]. Targeting the same product, Ma et al. used copper catalysis some years previously. The coupling of 1,4-diiodobenzene (41) and (S)-ethyl 3-amino-6-hydroxyhexanoate (42), and subsequent esterification resulted in an overall yield of 72% for the two steps to 43 [60,61]. The specific yield for the copper-catalysed reaction step was not reported.

Cu-catalysed synthesis of biological active molecules

Copper-catalysed N-arylation reactions were applied to introduce diversity into new ABCB1 transporter modulators. The tariquidar (44) derived compounds showed log P-dependent inhibition activity of the ABCB1 transporter, which represents an important component of the blood–brain barrier and is a major limitation in cancer chemotherapy.

Primary and cyclic secondary amines were coupled to 45 to give moderate to good yields of 49 and 50. Secondary acyclic amines 48 were unreactive: A variety of different conditions were investigated including the variation of base, ligand and copper source. Scheme 10 shows the optimized conditions for coupling with morpholine (46) and 2-(2-methoxyethoxy)ethanamine (47). Palladium-catalysed reactions failed due to the low solubility of the bromo compound in toluene [62].


Scheme 10: New tariquidar-derived ABCB1 inhibitors.

Another class of compounds used in anti-tumour treatment are β-carbolin-1-ones 52 due to their inhibition of cell proliferation. These compounds were accessible via intramolecular coupling between an aryl bromide and an acylated amine 51). In comparison to the Goldberg reaction conditions (CuI, NaH, DMF at 90 °C for 2 h), the change of the solvent to DME was crucial a gave good yields of up to 72% (Scheme 11). Additionally, the reaction was sensitive to the amount of NaH employed. Substituents on the aryl bromide affected the yield only marginally [63].


Scheme 11: β-Carbolin-1-ones as inhibitors of tumour cell proliferation.

A second example of intramolecular coupling is the synthesis of promazine drugs (56) that are interesting due to their clinical use for psychotropic medication. The CuI/L-proline-catalysed cascade process, developed by Ma et al., gave the best yields when 2-methoxyethanol was used as solvent, compared to DMSO, dioxane etc. The reaction conditions tolerated both electron-rich and electron-deficient substituents on the aniline 53 and on the 2-bromobenzenethiol 54 in different substitution patterns. This reaction is thought to proceed via intermediate 55. The catalytic synthetic sequence is an inexpensive and efficient route to the target compounds (Scheme 12) [64]. A three-component coupling reaction of 2-bromobenzenethiol 57, a primary amine 58 and 1-bromo-2-iodobenzenes 59, also targeting promazine derivatives 60, was successfully under palladium catalysis (Scheme 13). The method benefits from controlled regiochemistry and is applicable to various aliphatic and aromatic amines 58. Although the reaction scope was limited to 1-bromo-2-iodobenzenes 59, scale-up to multigram quantities was possible [65].


Scheme 12: Copper-catalysed synthesis of promazine drugs.


Scheme 13: Palladium-catalysed multicomponent reaction for the synthesis of promazine drugs.

A key intermediate 64 of imatinib 61, a standard anti-cancer drug for the treatment of chronic myelogenous leukaemia and gastrointestinal tumours, was prepared in 82% yield via copper-mediated N-arylation of 62 and 63 (Scheme 14). By screening different reaction conditions, Cu(I) was found to be the best copper source compared to Cu(0) and Cu(II). In the series of aryl halides, aryl iodides 63 were the most active. The presence of air and water gave only slightly lower yields. Other heteroarylamines also gave good yields [39].


Scheme 14: Key intermediate for imatinib.

The copper-catalysed domino-indole synthesis facilitated access to new Chek1/KDR kinase inhibitors 67 from phenylethynylnaphthalenes 65 and tert-butyl carbamate (66) (Scheme 15). The broad scope of this method improved the synthesis of diversely substituted indoles. In addition, N–H, N-acyl and N-aryl indoles were accessible. In this case, DMEDA turned out to be the crucial ligand [66].


Scheme 15: Synthesis of an effective Chek1/KDR kinase inhibitor.

Examples for the synthesis of complex biologically active compounds are reblastatin (68) and autolytimycin (69). These potent inhibitors of heat shock protein 90, an important therapeutic target for cancer treatment, were accessed by a copper-mediated macrocyclization step of 70 to 71 in high yield (82%, Scheme 16) [67]. The same method was employed in the total synthesis of geldanamycin and other 8- to 14-membered lactam-containing natural products [68].


Scheme 16: Macrocyclization as final step of the synthesis of heat shock protein inhibitor.

A number of biological targets, such as blocking cytochrome C oxidase, have made N-arylhistidines 74 important drug candidates. The quite simple-looking copper triflate-catalysed conversion of aryl halides 72 with the N-acylhistidine 73 was total regioselective on the imidazole ring, but suffered from complicated isolation procedures due to difficulties in separating the product from stoichiometric quantities of the ligand. Sufficient reactivity was only observed for aryl iodides and low overall yields were observed including at the subsequent ester cleavage step (Scheme 17) [69].


Scheme 17: Synthesis of N-arylimidazoles.

In the well-known synthesis of benzolactam V8 (78) [70], Ma et al. proved the accelerating effect of α- (76) and β-amino acids (80) on aryl aminations (Scheme 18 and Scheme 19). Lotrafiban (SB-214857, 79), a potent GPIIb/IIIa receptor antagonist inhibiting platelet aggregation, was efficiently obtained by an Ullmann-type aryl amination reaction. Despite the disadvantage of long reaction time (2 days), the intermediate 81 was obtained in enantiopure form [71].


Scheme 18: Synthesis of benzolactam V8.


Scheme 19: Synthesis of an intermediate for lotrafiban (SB-214857).

The very similar intermediate 85, published at the same time, was synthesized by the coupling of L-aspartic acid (83) to aryl bromide 82 in 55% yield and 90% ee (Scheme 20). Under these reaction conditions, CuI was found to be the copper source that caused the least amount of racemization [72].


Scheme 20: Intermolecular effort towards lotrafiban.

Chan–Lam arylation in the synthesis of biologically active molecules

A key intermediate (88) for the potent matrix metalloproteases (MMPs) inhibitor AG3433 (89) was synthesized by coupling an electron-deficient pyrrole (86) with an arylboronic acid (87) in excellent yield (93%, Scheme 21). Screening numerous boronic acids it was found that only boronic acids containing electron-donating or weakly electron-withdrawing substituents were suitable. Pyrroles lacking a substituent in the 2-position, which is supposed to support the reaction by a chelating effect with the copper ion, did not succeed in the coupling reaction. Further disadvantages were the required stoichiometric amount of copper and the long reaction time of 3 days [42].


Scheme 21: Synthesis of matrix metalloproteases (MMPs) inhibitor.

For detailed insight into the structural requirements of active antimycobacterial purines 90, an easy access to 9-N-arylpurines 93 was required. Complete regioselectivity, and in most cases high chemoselectivity, was achieved by reacting 9-N-purines 91 with an excess of arylboronic acid 92 in the presence of copper(II) acetate, molecular sieves and phenanthroline (Scheme 22). Bakkestuen and Gundersen showed that electron-donating and electron-withdrawing substituents on the arylboronic acid were tolerated. However, adenine was unreactive under these conditions, probably due to its low solubility [73].


Scheme 22: Regioselective 9-N-arylation of purines.

Slight changes of the procedure, the use of a protic solvent, enabled the conversion of adenine (97) and cytosine (94) (Scheme 23). These conditions tolerated both electron-donating and electron-withdrawing substituents at the o-, m-, p-positions in the phenylboronic acid (98) and resulted in moderate to excellent yields [74].


Scheme 23: N-Arylation of adenine and cytosine.

9-N-Arylpurines 102 and 105 are used as a new class of inhibitors against enteroviruses, which are responsible for a variety of acute human diseases such as respiratory infections, meningitis, pancreatitis and others. The conditions reported by Bakkestuen and Gundersen [73] gave only a low yield (26%). DMF as solvent and the absence of molecular sieves improved the yield (Scheme 24). The reaction conditions were compatible for different purine bases (100, 103) and for a variety of functional groups in the arylboronic acid (101, 104). Thus, a single reaction step from commercial precursors allowed the synthesis of new enterovirus inhibitors with activity in the low µM range [75].


Scheme 24: 9-N-Arylpurines as enterovirus inhibitors.

A very recent example of 7-N-arylation of purines is the synthesis of highly substituted xanthine derivatives 109 as fluorescent and potent kinase inhibitors. The conditions of Bakkestuen et al. were modified and gave yields of up to 60% for the optimized conditions with pyridine as the base and heating the reaction mixture to 40 °C for 24 h (Scheme 25). In addition to the p-methoxy substituent in the boronic acid 107, p-methyl and m-fluoro substituents were also tolerated. The xanthine compounds showed good anti-proliferative activity and exhibited a significant fluorescence response [76].


Scheme 25: Xanthine analogues as kinase inhibitors.

The peroxisome proliferator-activated receptors (PPARs), members of the nuclear hormone receptor superfamily, are important targets in the treatment of diabetes and dyslipidemia. Azetidinone acid derivatives 110 were discovered to be new subtype-selective PPARα/γ agonists. For detailed structure–activity relationship (SAR) studies, diversity was introduced very efficiently by a copper-mediated N-arylation of azetidinones 111 with different arylboronic acids 112 to give 113 in nearly quantitative yields (Scheme 26) [77]. The palladium-catalysed N-arylation of 2-azetidinones was only previously described for unsubstituted azetidinones [78].


Scheme 26: Synthesis of dual PPARα/γ agonists.

N-Aryltriazole ribonucleosides 118 with potent anti-proliferative activity against drug-resistant pancreatic cancer were prepared by coupling 3-aminotriazole with various boronic acids. Similar to the method developed for N-aryltriazole acylonucleoside analogues [79], N-arylation was performed in the presence of slightly greater than a stoichiometric amount of Cu(OAc)2, pyridine and freshly activated molecular sieves in CH2Cl2 at room temperature and the open air for 3 days (Scheme 27). There was no clear trend as to the effect of electron-donating or electron-withdrawing substituents of the arylboronic acid 116 on the course of the reaction. However, sterically hindered, ortho-substituted arylboronic reagents were unreactive. Although the coupling resulted only in moderate yields, a new anti-cancer drug candidate with improved potency on human pancreatic cancer cells, compared to gemcitabine (114), was obtained [80].


Scheme 27: N-Aryltriazole ribonucleosides with anti-proliferative activity.


Palladium- and copper-mediated N-arylations have been shown to be powerful methods for introducing aryl and heteroaryl substituents. However, for substrates with more complex structures, the performance and applicability of the different reactions are often difficult to predict. The three reaction types, palladium-catalysed and copper-catalysed N-arylations of aryl halides, and copper-catalysed N-arylations using boronic acids show some distinct differences. Palladium-catalysed N-arylation reactions typically require reaction temperatures of 80–130 °C and prolonged reaction times up to 40 h. In most of the cases, the reactions must be conducted under an inert atmosphere; toluene is a favourite solvent and BINAP a commonly used ligand. Strong bases are required and water is added to dissolve them. Substituents in the starting material, which are base labile are not tolerated. With low catalyst loading and good availability of the palladium sources, reactions on a larger scale are possible. Sterically demanding N-nucleophiles, as well as cyclic and aromatic amino compounds, are suitable coupling partners with aryl bromides.

In contrast to palladium catalysis, Ullmann-type coupling reactions tolerate atmospheric oxygen. However, reaction temperatures (90–115 °C) and reaction times (48 h) are comparable to the palladium-catalysed processes. Ligand-free and ligand-assisted reaction conditions have been applied in the synthesis of biologically active compounds. DMEDA, proline and phenanthroline are the most commonly used ligands. In some cases, the up to stoichiometric amount of ligand made work-up procedures difficult. In general, CuI is the most efficient catalyst. The reaction conditions are applicable to primary, cyclic secondary aliphatic amines, electron-rich and electron-poor anilines, and heteroarylamines. Macrocyclization using amides and aryl bromides is possible. Both palladium-catalysed and Ullmann-type N-arylation reactions were successfully applied for both inter- and intramolecular reactions. An advantage of the Ullmann-type reactions is the lower cost of catalyst metal salts and ligands.

The mildest conditions for N-arylation reactions are provided by the Chan–Lam arylation procedure, but conversion at room temperature requires long reaction times of up to 4 days. The general absence of ligands is an additional advantage facilitating product purification. However, 1–2 equiv of Cu(OAc)2 and large excess of boronic acid have to be used. Boronic acid reagents can have electron-donating and electron-withdrawing substituents in ortho-, meta- and para-positions, but boronic acids with sterically demanding substituents were found to be unreactive. Many precursors for the starting materials used in Chan–Lam arylations are commercially available.

None of the three reactions is clearly superior as method for all N-arylations. Depending on the substrate and the summarized constraints, the preferred method must be selected. In many cases optimization or adaptation of the standard protocols to the specific substrate is required. Nevertheless, the modern N-arylation methods have become an indispensable tool in organic chemistry and significantly facilitate the synthesis of complex natural products and drugs.


We acknowledge the support of the University of Regensburg and the Deutsche Forschungsgemeinschaft (GRK 760). We thank I. Krebs for providing the images and the composition of the graphical abstract.


  1. Ullmann, F. Ber. Dtsch. Chem. Ges. 1903, 36, 2382–2384. doi:10.1002/cber.190303602174
    Return to citation in text: [1]
  2. Ullmann, F.; Illgen, E. Ber. Dtsch. Chem. Ges. 1914, 47, 380–383. doi:10.1002/cber.19140470158
    Return to citation in text: [1]
  3. Goldberg, I. Ber. Dtsch. Chem. Ges. 1907, 40, 4541–4546. doi:10.1002/cber.19070400498
    Return to citation in text: [1]
  4. Monnier, F.; Taillefer, M. Angew. Chem., Int. Ed. 2009, 48, 6954–6971. doi:10.1002/anie.200804497
    Return to citation in text: [1] [2] [3]
  5. Goldberg, I. Ber. Dtsch. Chem. Ges. 1906, 39, 1691–1692. doi:10.1002/cber.19060390298
    Return to citation in text: [1]
  6. Muci, A. R.; Buchwald, S. L. Top. Curr. Chem. 2002, 219, 131–209. doi:10.1007/3-540-45313-X_5
    Return to citation in text: [1]
  7. Guram, A. S.; Rennels, R. A.; Buchwald, S. L. Angew. Chem., Int. Ed. 1995, 34, 1348–1350. doi:10.1002/anie.199513481
    Return to citation in text: [1]
  8. Hartwig, J. F. Angew. Chem., Int. Ed. 1998, 37, 2046–2067. doi:10.1002/(SICI)1521-3773(19980817)37:15<2046::AID-ANIE2046>3.0.CO;2-L
    Return to citation in text: [1]
  9. Louie, J.; Hartwig, J. F. Tetrahedron Lett. 1995, 36, 3609–3612. doi:10.1016/0040-4039(95)00605-C
    Return to citation in text: [1]
  10. Chan, D. M. T.; Monaco, K. L.; Wang, R.-P.; Winters, M. P. Tetrahedron Lett. 1998, 39, 2933–2936. doi:10.1016/S0040-4039(98)00503-6
    Return to citation in text: [1]
  11. Lam, P. Y. S.; Clark, C. G.; Saubern, S.; Adams, J.; Winters, M. P.; Chan, D. M. T.; Combs, A. Tetrahedron Lett. 1998, 39, 2941–2944. doi:10.1016/S0040-4039(98)00504-8
    Return to citation in text: [1]
  12. Lam, P. Y. S.; Clark, C. G.; Saubern, S.; Adams, J.; Averill, K. M.; Chan, D. M. T.; Combs, A. Synlett 2000, 674–676. doi:10.1055/s-2000-6628
    Return to citation in text: [1]
  13. Collman, J. P.; Zhong, M. Org. Lett. 2000, 2, 1233–1236. doi:10.1021/ol000033j
    Return to citation in text: [1]
  14. Collman, J. P.; Zhong, M.; Zeng, L.; Costanzo, S. J. Org. Chem. 2001, 66, 1528–1531. doi:10.1021/jo0016780
    Return to citation in text: [1] [2]
  15. Matsubara, K.; Ueno, K.; Koga, Y.; Hara, K. J. Org. Chem. 2007, 72, 5069–5076. doi:10.1021/jo070313d
    Return to citation in text: [1]
  16. Brenner, E.; Schneider, R.; Fort, Y. Tetrahedron 2002, 58, 6913–6924. doi:10.1016/S0040-4020(02)00750-0
    Return to citation in text: [1]
  17. Wolfe, J. P.; Buchwald, S. L. J. Org. Chem. 2000, 65, 1144–1157. doi:10.1021/jo9916986
    Return to citation in text: [1] [2] [3] [4]
  18. Rataboul, F.; Zapf, A.; Jackstell, R.; Harkal, S.; Riermeier, T.; Monsees, A.; Dingerdissen, U.; Beller, M. Chem.–Eur. J. 2004, 10, 2983–2990. doi:10.1002/chem.200306026
    Return to citation in text: [1] [2]
  19. Huang, X.; Anderson, K. W.; Zim, D.; Jiang, L.; Klapars, A.; Buchwald, S. L. J. Am. Chem. Soc. 2003, 125, 6653–6655. doi:10.1021/ja035483w
    Return to citation in text: [1]
  20. Old, D. W.; Harris, M. C.; Buchwald, S. L. Org. Lett. 2000, 2, 1403–1406. doi:10.1021/ol005728z
    Return to citation in text: [1]
  21. Buchwald, S. L.; Mauger, C.; Mignani, G.; Scholz, U. Adv. Synth. Catal. 2006, 348, 23–39. doi:10.1002/adsc.200505158
    Return to citation in text: [1]
  22. Viciu, M. S.; Kelly, R. A., III; Stevens, E. D.; Naud, F.; Studer, M.; Nolan, S. P. Org. Lett. 2003, 5, 1479–1482. doi:10.1021/ol034264c
    Return to citation in text: [1]
  23. Organ, M. G.; Abdel-Hadi, M.; Avola, S.; Dubovyk, I.; Hadei, N.; Kantchev, E. A. B.; O'Brien, C. J.; Sayah, M.; Valente, C. Chem.–Eur. J. 2008, 14, 2443–2452. doi:10.1002/chem.200701621
    Return to citation in text: [1]
  24. Grasa, G. A.; Viciu, M. S.; Huang, J.; Nolan, S. P. J. Org. Chem. 2001, 66, 7729–7737. doi:10.1021/jo010613+
    Return to citation in text: [1]
  25. Barluenga, J.; Jiménez-Aquino, A.; Aznar, F.; Valdés, C. J. Am. Chem. Soc. 2009, 131, 4031–4041. doi:10.1021/ja808652a
    Return to citation in text: [1]
  26. Grauer, A.; Späth, A.; Ma, D. W.; König, B. Chem.–Asian J. 2009, 4, 1134–1140. doi:10.1002/asia.200900033
    Return to citation in text: [1]
  27. Antilla, J. C.; Baskin, J. M.; Barder, T. E.; Buchwald, S. L. J. Org. Chem. 2004, 69, 5578–5587. doi:10.1021/jo049658b
    Return to citation in text: [1]
  28. Antilla, J. C.; Klapars, A.; Buchwald, S. L. J. Am. Chem. Soc. 2002, 124, 11684–11688. doi:10.1021/ja027433h
    Return to citation in text: [1]
  29. Altman, R. A.; Koval, E. D.; Buchwald, S. L. J. Org. Chem. 2007, 72, 6190–6199. doi:10.1021/jo070807a
    Return to citation in text: [1]
  30. Lam, P. Y. S.; Deudon, S.; Averill, K. M.; Li, R.; He, M. Y.; DeShong, P.; Clark, C. G. J. Am. Chem. Soc. 2000, 122, 7600–7601. doi:10.1021/ja001305g
    Return to citation in text: [1]
  31. Lam, P. Y. S.; Vincent, G.; Bonne, D.; Clark, C. G. Tetrahedron Lett. 2002, 43, 3091–3094. doi:10.1016/S0040-4039(02)00356-8
    Return to citation in text: [1]
  32. Beringer, F. M.; Brierley, A.; Drexler, M.; Gindler, E. M.; Lumpkin, C. C. J. Am. Chem. Soc. 1953, 75, 2708–2712. doi:10.1021/ja01107a047
    Return to citation in text: [1]
  33. Lopez-Alvarado, P.; Avendano, C.; Menendez, J. C. J. Org. Chem. 1995, 60, 5678–5682. doi:10.1021/jo00122a060
    Return to citation in text: [1]
  34. Barton, D. H. R.; Finet, J.-P. Pure Appl. Chem. 1987, 59, 937–946. doi:10.1351/pac198759080937
    Return to citation in text: [1]
  35. Strouse, J. J.; Jeselnik, M.; Arterburn, J. B. Acta Chim. Slov. 2005, 52, 187–199.
    Return to citation in text: [1]
  36. Attenberger, B.; Schmaderer, H.; König, B. Synthesis 2008, 1767–1774. doi:10.1055/s-2008-1067045
    Return to citation in text: [1]
  37. Lan, J.-B.; Chen, L.; Yu, X.-Q.; You, J.-S.; Xie, R.-G. Chem. Commun. 2004, 188–189. doi:10.1039/B307734A
    Return to citation in text: [1] [2] [3]
  38. Lan, J.-B.; Zhang, G.-L.; Yu, X.-Q.; You, J.-S.; Chen, L.; Yan, M.; Xie, R.-G. Synlett 2004, 1095–1097. doi:10.1055/s-2004-820059
    Return to citation in text: [1] [2] [3] [4]
  39. Liu, Y.; Bai, Y.; Zhang, J.; Li, Y.; Jiao, J.; Qi, X. Eur. J. Org. Chem. 2007, 6084–6088. doi:10.1002/ejoc.200700577
    Return to citation in text: [1] [2]
  40. Wentzel, M. T.; Hewgley, J. B.; Kamble, R. M.; Wall, P. D.; Kozlowski, M. C. Adv. Synth. Catal. 2009, 351, 931–937. doi:10.1002/adsc.200800730
    Return to citation in text: [1] [2]
  41. Nishiura, K.; Urawa, Y.; Soda, S. Adv. Synth. Catal. 2004, 346, 1679–1684. doi:10.1002/adsc.200404193
    Return to citation in text: [1]
  42. Yu, S.; Saenz, J.; Srirangam, J. K. J. Org. Chem. 2002, 67, 1699–1702. doi:10.1021/jo016131f
    Return to citation in text: [1] [2]
  43. Browning, R. G.; Badarinarayana, V.; Mahmud, H.; Lovely, C. J. Tetrahedron 2004, 60, 359–365. doi:10.1016/j.tet.2003.11.008
    Return to citation in text: [1]
  44. Monnier, F.; Taillefer, M. Angew. Chem., Int. Ed. 2008, 47, 3096–3099. doi:10.1002/anie.200703209
    Return to citation in text: [1]
  45. Evano, G.; Blanchard, N.; Toumi, M. Chem. Rev. 2008, 108, 3054–3131. doi:10.1021/cr8002505
    Return to citation in text: [1] [2]
  46. Beletskaya, I. P.; Cheprakov, A. V. Coord. Chem. Rev. 2004, 248, 2337–2364. doi:10.1016/j.ccr.2004.09.014
    Return to citation in text: [1]
  47. Carril, M.; SanMartin, R.; Domínguez, E. Chem. Soc. Rev. 2008, 37, 639–647. doi:10.1039/B709565C
    Return to citation in text: [1]
  48. Ley, S. V.; Thomas, A. W. Angew. Chem., Int. Ed. 2003, 42, 5400–5449. doi:10.1002/anie.200300594
    Return to citation in text: [1]
  49. Campiani, G.; Butini, S.; Trotta, F.; Fattorusso, C.; Catalanotti, B.; Aiello, F.; Gemma, S.; Nacci, V.; Novellino, E.; Stark, J. A.; Cagnotto, A.; Fumagalli, E.; Carnovali, F.; Cervo, L.; Mennini, T. J. Med. Chem. 2003, 46, 3822–3839. doi:10.1021/jm0211220
    Return to citation in text: [1]
  50. Federsel, H.-J.; Hedberg, M.; Qvarnström, F. R.; Sjögren, M. P. T.; Tian, W. Acc. Chem. Res. 2007, 40, 1377–1384. doi:10.1021/ar700102c
    Return to citation in text: [1]
  51. Federsel, H.-J.; Hedberg, M.; Qvarnström, F. R.; Tian, W. Org. Process Res. Dev. 2008, 12, 512–521. doi:10.1021/op8000146
    Return to citation in text: [1]
  52. Ji, J.; Bunnelle, W. H.; Li, T.; Pace, J. M.; Schrimpf, M. R.; Sippy, K. B.; Anderson, D. J.; Meyer, M. D. Pure Appl. Chem. 2005, 77, 2041–2045. doi:10.1351/pac200577122041
    Return to citation in text: [1]
  53. Carril, M.; SanMartin, R.; Churruca, F.; Tellitu, I.; Domínguez, E. Org. Lett. 2005, 7, 4787–4789. doi:10.1021/ol051291p
    Return to citation in text: [1]
  54. Carril, M.; SanMartin, R.; Domínguez, E.; Tellitu, I. Tetrahedron 2007, 63, 690–702. doi:10.1016/j.tet.2006.11.003
    Return to citation in text: [1]
  55. Takahashi, M.; Tanabe, H.; Nakamura, T.; Kuribara, D.; Yamazaki, T.; Kitagawa, O. Tetrahedron 2010, 66, 288–296. doi:10.1016/j.tet.2009.10.095
    Return to citation in text: [1]
  56. Fletcher, A. J.; Bax, M. N.; Willis, M. C. Chem. Commun. 2007, 4764–4766. doi:10.1039/B712227F
    Return to citation in text: [1]
  57. Ueno, A.; Kitawaki, T.; Chida, N. Org. Lett. 2008, 10, 1999–2002. doi:10.1021/ol800602v
    Return to citation in text: [1]
  58. Mazzini, F.; Netscher, T.; Salvadori, P. Eur. J. Org. Chem. 2009, 2063–2068. doi:10.1002/ejoc.200900088
    Return to citation in text: [1]
  59. Miyata, O.; Shirai, A.; Yoshino, S.; Takeda, Y.; Sugiura, M.; Naito, T. Synlett 2006, 893–896. doi:10.1055/s-2006-939046
    Return to citation in text: [1]
  60. Ma, D.; Xia, C.; Jiang, J.; Zhang, J. Org. Lett. 2001, 3, 2189–2191. doi:10.1021/ol016043h
    Return to citation in text: [1]
  61. Ma, D.; Xia, C.; Jiang, J.; Zhang, J.; Tang, W. J. Org. Chem. 2003, 68, 442–451. doi:10.1021/jo026125z
    Return to citation in text: [1]
  62. Egger, M.; Li, X. Q.; Müller, C.; Bernhardt, G.; Buschauer, A.; König, B. Eur. J. Org. Chem. 2007, 2643–2649. doi:10.1002/ejoc.200700142
    Return to citation in text: [1]
  63. Wang, S.; Dong, Y.; Wang, X.; Hu, X.; Liu, J. O.; Hu, Y. Org. Biomol. Chem. 2005, 3, 911–916. doi:10.1039/B412921K
    Return to citation in text: [1]
  64. Ma, D.; Geng, Q.; Zhang, H.; Jiang, Y. Angew. Chem., Int. Ed. 2010, 49, 1291–1294. doi:10.1002/anie.200905646
    Return to citation in text: [1]
  65. Dahl, T.; Tornøe, C. W.; Bang-Andersen, B.; Nielsen, P.; Jørgensen, M. Angew. Chem., Int. Ed. 2008, 47, 1726–1728. doi:10.1002/anie.200705209
    Return to citation in text: [1]
  66. Ackermann, L.; Barfüßer, S.; Potukuchi, H. K. Adv. Synth. Catal. 2009, 351, 1064–1072. doi:10.1002/adsc.200900004
    Return to citation in text: [1]
  67. Wrona, I. E.; Gozman, A.; Taldone, T.; Chiosis, G.; Panek, J. S. J. Org. Chem. 2010, 75, 2820–2835. doi:10.1021/jo1000109
    Return to citation in text: [1]
  68. Qin, H.-L.; Panek, J. S. Org. Lett. 2008, 10, 2477–2479. doi:10.1021/ol800749w
    Return to citation in text: [1]
  69. Yue, W.; Lewis, S. I.; Koen, Y. M.; Hanzlik, R. P. Bioorg. Med. Chem. Lett. 2004, 14, 1637–1640. doi:10.1016/j.bmcl.2004.01.058
    Return to citation in text: [1]
  70. Ma, D.; Zhang, Y.; Yao, J.; Wu, S.; Tao, F. J. Am. Chem. Soc. 1998, 120, 12459–12467. doi:10.1021/ja981662f
    Return to citation in text: [1]
  71. Ma, D.; Xia, C. Org. Lett. 2001, 3, 2583–2586. doi:10.1021/ol016258r
    Return to citation in text: [1]
  72. Clement, J.-B.; Hayes, J. F.; Sheldrake, H. M.; Sheldrake, P. W.; Wells, A. S. Synlett 2001, 1423–1427. doi:10.1055/s-2001-16780
    Return to citation in text: [1]
  73. Bakkestuen, A. K.; Gundersen, L.-L. Tetrahedron Lett. 2003, 44, 3359–3362. doi:10.1016/S0040-4039(03)00576-8
    Return to citation in text: [1] [2]
  74. Yue, Y.; Zheng, Z.-G.; Wu, B.; Xia, C.-Q.; Yu, X.-Q. Eur. J. Org. Chem. 2005, 5154–5157. doi:10.1002/ejoc.200500589
    Return to citation in text: [1]
  75. Aguado, L.; Thibaut, H. J.; Priego, E.-M.; Jimeno, M.-L.; Camarasa, M.-J.; Neyts, J.; Pérez-Pérez, M.-J. J. Med. Chem. 2010, 53, 316–324. doi:10.1021/jm901240p
    Return to citation in text: [1]
  76. Kim, D.; Jun, H.; Lee, H.; Hong, S.-S.; Hong, S. Org. Lett. 2010, 12, 1212–1215. doi:10.1021/ol100011n
    Return to citation in text: [1]
  77. Wang, W.; Devasthale, P.; Farrelly, D.; Gu, L. Q.; Harrity, T.; Cap, M.; Chu, C. X.; Kunselman, L.; Morgan, N.; Ponticiello, R.; Zebo, R.; Zhang, L.; Locke, K.; Lippy, J.; O'Malley, K.; Hosagrahara, V.; Zhang, L.; Kadiyala, P.; Chang, C.; Muckelbauer, J.; Doweyko, A. M.; Zahler, R.; Ryono, D.; Hariharan, N.; Cheng, P. T. W. Bioorg. Med. Chem. Lett. 2008, 18, 1939–1944. doi:10.1016/j.bmcl.2008.01.126
    Return to citation in text: [1]
  78. Yin, J.; Buchwald, S. L. Org. Lett. 2000, 2, 1101–1104. doi:10.1021/ol005654r
    Return to citation in text: [1]
  79. Li, W.; Fan, Y.; Xia, Y.; Rocchi, P.; Zhu, R.; Qu, F.; Neyts, J.; Iovanna, J. L.; Peng, L. Helv. Chim. Acta 2009, 92, 1503–1513. doi:10.1002/hlca.200900033
    Return to citation in text: [1]
  80. Liu, Y.; Xia, Y.; Fan, Y.; Maggiani, A.; Rocchi, P.; Qu, F.; Iovanna, J. L.; Peng, L. Bioorg. Med. Chem. Lett. 2010, 20, 2503–2507. doi:10.1016/j.bmcl.2010.02.104
    Return to citation in text: [1]

© 2011 Fischer and Koenig; licensee Beilstein-Institut.
This is an Open Access article under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The license is subject to the Beilstein Journal of Organic Chemistry terms and conditions: (

Back to Article List